Metabolic Liver Disease: The Shift to MASH and Breakthrough Obesity Therapies
A significant paradigm shift is reshaping our understanding of fatty liver disease in patients without significant alcohol consumption. The condition formerly known as Non-Alcoholic Steatohepatitis (NASH) has been reconceptualized as Metabolic Dysfunction-Associated Steatohepatitis (MASH), acknowledging its fundamental connection to systemic metabolic abnormalities. This evolution in terminology coincides with revolutionary advances in treatment approaches, particularly the […]
